FDA Authorizes Moderna's mRNA Flu Vaccine for Older Adults

The U.S. FDA has granted approval to Moderna's mFlusiva (mRNA-1010), making it the first mRNA-based seasonal influenza vaccine authorized in the U.S. This vaccine is indicated for adults aged 50 and older, with accelerated approval for those 65 and above based on immunogenicity data. It is expected to be available for the 2026-2027 respiratory virus season, marking a significant advancement in vaccine technology.